Scholarlink

<p>Myeloproliferative neoplasms (MPNs) are associated with an elevated risk of thrombosis in unusual sites such as the splanchnic vein thrombosis (SVT) and cerebral vein thrombosis (CVT). In patients with unusual site thrombosis, screening for MPNs is routine, but diagnosis is often difficult due to the absence of clear clinical signs or elevated blood counts—frequently leading to an MPN-U classification—while the thrombotic event itself is often the first clue. Furthermore, there is no consensus on treatments beyond anticoagulation, leading to variability across centers. This study investigates the molecular characteristics of MPNs associated with SVT and CVT. We conducted a retrospective, multicenter analysis of 44 patients with MPN and unusual site thrombosis from Italian hematology units, using next-generation sequencing. (NGS) to identify driver and passengers mutations. Our findings confirm a high prevalence of unclassifiable MPN (MPN-U) among SVT patients. <i>JAK2 p.V617F</i> was found in 86.4% of cases, and patients with additional mutations had higher median <i>JAK2</i> variant allele frequencies. <i>JAK2 p.V617F</i> is known to promote thrombosis by inducing a pro-inflammatory endothelial environment, particularly relevant in low-flow venous sites such as cerebral sinuses and splanchnic veins, supporting MPN screening in these patients. In contrast, data on <i>JAK2</i>-unmutated cases are more limited, but our cohort suggests a possible association between unusual site thrombosis and a more complex mutational profile involving multiple genetic alterations. TET2 mutations were more frequent in patients with MPN-CVT compared to the rest of the cohort (66.6% vs. 15.7%). Absence of <i>KIT</i> mutations was associated with poorer thrombotic recurrence-free survival, suggesting a negative prognostic role of <i>KIT</i> mutation. Brief report.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Genetic insights into myeloproliferative neoplasms and unusual sites thrombosis

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年9月29日

查看全文
  • Erika Morsia,
  • Paola Ranalli,
  • Stefano Baldoni,
  • Stefania. Mancini,
  • Sonia Morè,
  • Chiara Cantò,
  • Dorela Lame,
  • Gaetano La Barba,
  • Antonella Poloni,
  • Serena Rupoli,
  • Mauro Di Ianni

摘要

Myeloproliferative neoplasms (MPNs) are associated with an elevated risk of thrombosis in unusual sites such as the splanchnic vein thrombosis (SVT) and cerebral vein thrombosis (CVT). In patients with unusual site thrombosis, screening for MPNs is routine, but diagnosis is often difficult due to the absence of clear clinical signs or elevated blood counts—frequently leading to an MPN-U classification—while the thrombotic event itself is often the first clue. Furthermore, there is no consensus on treatments beyond anticoagulation, leading to variability across centers. This study investigates the molecular characteristics of MPNs associated with SVT and CVT. We conducted a retrospective, multicenter analysis of 44 patients with MPN and unusual site thrombosis from Italian hematology units, using next-generation sequencing. (NGS) to identify driver and passengers mutations. Our findings confirm a high prevalence of unclassifiable MPN (MPN-U) among SVT patients. JAK2 p.V617F was found in 86.4% of cases, and patients with additional mutations had higher median JAK2 variant allele frequencies. JAK2 p.V617F is known to promote thrombosis by inducing a pro-inflammatory endothelial environment, particularly relevant in low-flow venous sites such as cerebral sinuses and splanchnic veins, supporting MPN screening in these patients. In contrast, data on JAK2-unmutated cases are more limited, but our cohort suggests a possible association between unusual site thrombosis and a more complex mutational profile involving multiple genetic alterations. TET2 mutations were more frequent in patients with MPN-CVT compared to the rest of the cohort (66.6% vs. 15.7%). Absence of KIT mutations was associated with poorer thrombotic recurrence-free survival, suggesting a negative prognostic role of KIT mutation. Brief report.